AndroGel & the Transdermal Gels
AbbVie AndroGel, Testim, Fortesta, Vogelxo, Axiron
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- FDA Approved (AndroGel 2000)
Reference only. Not medical advice.
What can go wrong
Transference is the signature risk. Absorption is variable; skin reactions occur. AndroGel's marketing history is the cautionary tale of the 'Low T' era and FDA's 2015 labeling action.
This is something to take to a clinician. The Atlas can tell you what is known about androgel & the transdermal gels in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Transdermal testosterone gels deliver testosterone through the skin daily. AndroGel (AbbVie, approved 2000) was the commercial engine of the 2000s 'Low T' marketing boom and the subject of the FDA's 2015 action against age-related-decline advertising. The class includes Testim, Fortesta, Vogelxo, and Axiron (axillary). Gels give steady levels and avoid injections, but absorption varies between individuals and they carry a boxed warning for secondary transfer, skin contact can virilize female partners and children.
The product that built the 'Low T' market, and its transference warning.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
Safety in detail
Carries an FDA boxed warning about secondary exposure: transfer to women and children via skin contact can cause virilization. Requires physician oversight.
What it does to fertility
Suppresses spermatogenesis; not fertility-preserving.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total testosterone
- Hematocrit
- PSA (over 40)
What people get wrong
Often saidGels are safer than injections
ActuallyDifferent risk profile, not safer overall: gels avoid needles but add transference risk to family members and more variable absorption.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Lead product
- AndroGel (AbbVie, 2000)
- Others
- Testim, Fortesta, Vogelxo, Axiron
- Boxed warning
- Secondary transfer to women/children
- Application
- Daily, to skin (or axilla for Axiron)
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about AndroGel & the Transdermal Gels. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
No sources recorded for this entry yet. Nothing on this page can be checked against a citation until that changes, so treat it as a summary awaiting its evidence.